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Aims Drug-eluting stents (DES) may be associated with an increased risk for stent thrombosis when compared with bare-
metal stents. In endothelial cells, rapamycin induces tissue factor (TF) by inhibiting the mammalian target of rapamycin
(mTOR). However, the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been
studied. Moreover, it is unclear whether second-generation DES substances everolimus and zotarolimus have an
effect on endothelial TF expression.
Methods
and results
In a mouse carotid artery photochemical injury model, rapamycin (182+27.5 mg/L) decreased time to thrombotic
occlusion by 40%, increased TF activity, and abrogated p70S6K phosphorylation when compared with controls.
In vitro, rapamycin, everolimus, and zotarolimus (each 1027 mol/l) enhanced TNF-a-induced TF expression by
2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity. Similar to rapamycin,
everolimus and zotarolimus abrogated TNF-a-induced p70S6K phosphorylation under these conditions.
Conclusion Rapamycin increases TF activity and promotes arterial thrombosis in vivo at concentrations relevant in patients under-
going DES implantation; this effect may increase the thrombogenicity of DES. Since everolimus and zotarolimus
augment endothelial TF expression and activity in vitro in a similar manner as rapamycin, these findings may also
be relevant for second generation DES.
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Introduction
Percutaneous coronary intervention and stenting of the culprit
lesion is the preferred treatment in acute myocardial infarc-
tion.1– 3 Drug-eluting stents (DES) are associated with
reduced restenosis rates when compared with bare-metal stents
(BMS).4 –6 However, stent thrombosis rates are not reduced in
DES and may even be higher when compared with BMS, particu-
larly in acute coronary syndromes (ACS).6 –13 Since it is associated
with a high mortality, stent thrombosis remains one of the most
dreaded complications of interventional cardiology. Indeed, stent
thrombosis is believed to be one possible reason for the lack of
a true mortality benefit with DES when compared with BMS.14,15
Second-generation DES such as everolimus- and zotarolimus-
eluting stents are proposed to display a better safety profile com-
pared with first-generation DES, but long-term, large-scale clinical
data supporting this hypothesis are lacking.
Initiation of coagulation is a pivotal event in the pathogenesis of
thrombosis and acute myocardial infarction. Tissue factor (TF) is a
key trigger of the coagulation cascade; it activates factor X (FX) by
binding activated factor VII (FVIIa), which ultimately leads to
thrombin formation.16 Rapamycin, a macrocyclic lacton used on
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first-generation DES, induces TF in human endothelial cells by inhi-
biting the activity of the mammalian target of rapamycin (mTOR).17
However, the effect of mTOR inhibition on TF activity and throm-
bus formation in vivo has not yet been studied. Moreover, whether
and to what degree the rapamycin analogues everolimus and zotar-
olimus exert similar effects on endothelial TF expression is
unknown. Thus, the present study was designed to investigate
the role of mTOR inhibition on TF induction and arterial thrombo-
sis in vivo and to examine the effect of everolimus and zotarolimus
on TF expression human endothelial cells.
Methods
Carotid artery thrombosis model
C57BL/6 mice (6–8 weeks old; Charles River Laboratories, Sulzfeld,
Germany) weighing an average of 23+ 2 g were treated with rapamy-
cin (2 mg/kg body weight) or with vehicle by intraperitoneal injection.
After 1 h, mice were anesthetized with intraperitoneal injection of
2 mg of sodium pentobarbital (Butler, Columbus, OH, USA) as
described previously.18,19 Rose Bengal (Fisher Scientific, Fair Lawn,
NJ, USA) was diluted to 10 mg/mL in phosphate-buffered saline
(PBS) and then injected into the tail vein in a volume of 0.12 mL at a
final concentration of 50 mg/kg with a 27-gauge Precision Glide
needle with a 1 mL latex-free syringe (Becton Dickinson, Franklin
Lakes, NJ, USA). Once anesthetized, mice were secured in a supine
position, placed under a dissecting microscope (Olympus C-4040
Zoom; spatial resolution 4.1 megapixels, Olympus Schweiz, AG,
Switzerland), and the right common carotid artery was exposed
after a midline cervical incision. A Doppler flow probe (model 0.5
VB, Transonic Systems, Ithaca, NY, USA) was applied to the right
common carotid artery and connected to a flowmeter (Transonic,
model T106) thus enabling measurement of systolic and diastolic
blood flow. Six minutes after Rose Bengal injection, a 1.5 mW green
laser light (540 nm; Melles Griot, Carlsbad, CA, USA) was aimed at
the right carotid artery and kept at a distance of 6 cm for 60 min or
until thrombosis occurred. Exposure of the circulating Rose Bengal
to the green laser light triggered a photochemical reaction causing a
focal injury mainly confined to the endothelium. From the onset of
injury, blood flow in the vessel was monitored for 120 min, at which
time the experiment was terminated. Occlusion was defined as a
flow of 0.1 mL/min for at least 1 min.19,20 At the time of cessation
of blood flow, the appearance of an occlusive thrombus was clearly
visible through the microscope in the lumen of the artery.
Tissue factor activity in vitro and in vivo
Tissue factor cell surface and total tissue activity were analysed in
human aortic endothelial cells (HAEC) and mouse carotid artery
homogenates, respectively, with a colorimetric assay (American
Diagnostica) as described.19,21
HAEC were grown in 12-well plates; after stimulation, cells were
washed twice with PBS followed by incubation with human FVIIa and
FX at 378C, resulting in the formation of TF/FVIIa complex at the cell
surface. Right carotid arteries were homogenized in 50 mL of lysis
buffer (50 mmol Tris–HCl, 100 mmol NaCl, 0.1% Triton X-100, pH
7.4) 1 h after intraperitoneal application of rapamycin (2 mg/kg body
weight) or vehicle and left to stand on ice for 30 min. In either case,
the TF/FVIIa complex converted human FX to factor Xa, which was
measured by its ability to cleave a chromogenic substrate. A standard
curve with lipidated human TF was performed to ensure that measure-
ments were taken in the linear range of detection (data not shown).
Cell culture
HAEC were cultured as described.21 Cells were grown to confluence
in 3.5 cm dishes and rendered quiescent for 24 h before stimulation
with TNF-a (Sigma, Munich, Germany). Rapamycin, everolimus (both
from Sigma), and zotarolimus (a kind gift from Abbott Vascular,
Santa Clara, CA, USA) were added 60 min prior to stimulation.
Western blot analysis
Protein expression was determined by western blot analysis.17 Cells
were lysed in 50 mM Tris buffer and 30–40 mg samples were loaded
and separated by 10% SDS–PAGE. Proteins were transferred to a
PVDF membrane (Millipore, Billerica, MA, USA) by semidry transfer.
The antibody to human TF (American Diagnostica, Pfungstadt,
Germany) was used at 1:1000 dilution; antibodies against the phos-
phorylated Thr-389-residue of p70S6 kinase (S6K) and against total
S6K (both from Cell Signaling) were used at 1:1000 and 1:2000
dilution, respectively. Blots were normalized to GAPDH expression
(1:20 000 dilution, Sigma).
One hour after intraperitoneal application of rapamycin (2 mg/kg
body weight) or vehicle (2.5% DMSO in PBS), aortas of mice were
homogenized in 50 mL of lysis buffer (50 mmol Tris–HCl, 100 mmol
NaCl, 0.1% Triton X-100, pH 7.4) and left to stand on ice for
30 min. One hundred microgram samples were loaded and separated
by 10% SDS–PAGE; proteins were transferred to a PVDF membrane
and probed with an antibody to phosphorylated p70S6K (1:1000
dilution) or total p70S6K (1:2000 dilution).
Statistics
Data are presented as mean+ SD. For the comparison of two groups,
unpaired Student’s t-test and Mann–Whitney test were applied for
normally and non-normally distributed variables, respectively.
ANOVA with Bonferroni’s correction was used for comparison of
greater than or equal to three groups (all variables in multi-group com-
parisons were normally distributed). A P-value , 0.05 was considered
significant.
Results
Rapamycin inhibits mammalian target of
rapamycin, increases tissue factor
activity, and promotes arterial
thrombosis in vivo
Photochemically induced arterial injury, an established model of
arterial thrombosis,18– 20,22 was applied to study arterial thrombus
formation. Vehicle-treated mice developed thrombotic occlusion
within 36.0+15.6 min (Figure 1A left column). Treatment with
rapamycin (2 mg/kg body weight) shortened time to thrombotic
vessel occlusion by 40% to 21.4+6.4 min (P, 0.05; Figure 1A,
right column). Plasma levels of rapamycin 1 h after intraperitoneal
injection were 182 mg/L (+27.5 mg/L; n ¼ 4).
Photochemical arterial injury is dependent on TF.18 Treatment
of mice with rapamycin (2 mg/kg body weight) increased TF activity
in carotid arteries by 45% when compared with TF activity in
carotid arteries of vehicle-treated mice (Figure 1B; P ¼ 0.01).
Phosphorylation of p70S6K, a downstream target of mTOR, is
frequently used to assess mTOR inhibition by rapamycin,17,23,24
and abrogation of p70S6K phosphorylation leads to an
increase in TF expression and activity.17 While a prominent
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phosphorylation of p70S6K was observed in aortas of mice treated
with vehicle, it was abrogated in rapamycin-treated animals
(Figure 1C; P, 0.01).
There was no change in activated partial thromboplastin time
(25.5+ 1.22 vs. 24.4+1.81 s, P ¼ n.s.) or prothrombin time
(PT; 11.1+0.2 vs. 11.4+0.43 s, P ¼ n.s.) in rapamycin-treated
vs. control mice, respectively.
Rapamycin enhances tissue factor
expression in human endothelial cells
Stimulation of HAEC with TNF-a (5 ng/mL) induced TF protein
expression (Figure 2). Rapamycin (1029–1027 mol/L) resulted in
a concentration-dependent enhancement of TF expression with
a maximal increase of 1.9-fold when compared with stimulation
with TNF-a alone and 68-fold when compared with the unstimu-
lated control (Figure 2A; P, 0.02 for rapamycin 1027 mol/L vs.
TNF-a alone). Rapamycin (1027 mol/L) abrogated p70S6K phos-
phorylation (Figure 2B).
Everolimus and zotarolimus enhance
tissue factor expression in human
endothelial cells
Like rapamycin, everolimus (1029–1027 mol/L) and zotarolimus
(1029–1027 mol/L) enhanced TNF-a-induced TF expression in a
concentration-dependent manner (n ¼ 3; P, 0.05, data not
shown). When compared side-by-side (each substance 1027 mol/L),
the maximal increase in TF induction was 2.2-, 1.7-, and 2.4-fold for
rapamycin, everolimus, and zotarolimus, respectively, when compared
with TNF-a (Figure 3A; P, 0.005 for everolimus vs. TNF-a alone and
P, 0.001 for zotarolimus vs. TNF-a alone). Tissue factor induction by
zotarolimusþTNF-a was 1.4-fold higher when compared with
everolimusþTNF-a (P, 0.05).
Rapamycin increased TNF-a-induced TF surface activity by
1.5-fold; similarly, everolimus and zotarolimus augmented
TNF-a-induced TF surface activity by 1.4-fold and 1.5-fold,
respectively (Figure 3B; P, 0.01 for everolimus or zotarolimus
vs. TNF-a alone). Similar to rapamycin (Figure 2B), everolimus
(Figure 3C, upper panel) and zotarolimus (Figure 3C, lower panel)
abrogated TNF-a-induced p70S6K phosphorylation.
Discussion
Rapamycin was previously shown to induce TF in vitro; yet, the
physiological significance of this effect has not been assessed.17
The findings of the present study suggest that this effect is also rel-
evant in vivo, since inhibition of mTOR by rapamycin increases TF
activity and promotes arterial thrombosis in the mouse carotid
artery exposed to laser injury. Moreover, everolimus and zotaroli-
mus inhibit mTOR and enhance TF expression and activity in
human endothelial cells similar to rapamycin, indicating that
these findings may be relevant both for first- and second-
generation DES.
The inhibitory role of the mTOR on TF expression is estab-
lished, as its inhibition enhances TF expression in response to a
variety of mediators in vitro.17,19,25 Binding of rapamycin to its intra-
cellular receptor, FKBP-12, leads to the formation of the
rapamycin–FKBP-12 complex, which in turn inhibits mTOR
activity. Phosphorylation of the downstream target of mTOR,
p70S6K, is widely used as a readout for the inhibitory effect of
rapamycin,23,24 since mTOR-dependent phosphorylation of the
Thr-389 residue of p70S6K is necessary for its activity.23 Rapamy-
cin is known to abrogate p70S6K phosphorylation,17 and the
present study demonstrates that the rapamycin analogues
Figure 1 Rapamycin inhibits mammalian target of rapamycin
(mTOR), increases TF activity, and promotes arterial thrombosis
in vivo. (A) Treatment with rapamycin shortens time to thrombo-
tic carotid artery occlusion. *P, 0.05 vs. vehicle-treated mice;
n  6 for each group. (B) Rapamycin increases TF activity
in mouse carotid artery. Values are given as absorbance at
405 nm. *P ¼ 0.01 vs. vehicle-treated mice, n ¼ 5 for each
group. (C) Treatment with rapamycin inhibits mTOR activity in
vivo as evidenced by reduced p70S6K phosphorylation.
*P, 0.01 vs. vehicle-treated mice, n ¼ 5 for each group.
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everolimus and zotarolimus equally do so, supporting the
interpretation that inhibition of mTOR promotes TF induction.17
Biologically active TF (which is located at the cell surface) is
induced by all three drugs to a very similar degree in vitro. In the
case of rapamycin and zotarolimus, the increase in TF surface
activity was not as pronounced as that in protein expression.
Similar discrepancies between the degree of protein expression
and surface activity have also been observed in previous
studies,17,21 and may be accounted for by the expression of
encrypted TF and/or the distribution of TF in several cellular
compartments.26
The dose of rapamycin used in our in vivo experiments (2 mg/kg
body weight) corresponds to that employed in previous murine
studies.27 Rapamycin plasma levels 1 h after intraperitoneal injec-
tion (i.e. at the time of thrombosis) were 182 mg/L, corresponding
to 2  1027 mol/L; hence, plasma levels in vivo were similar to the
concentrations employed in vitro. Maximal systemic concentrations
of rapamycin after deployment of two sirolimus-eluting stents are
reported to be 1 ng/mL (1.15  1029 mol/L).28 Although diffi-
cult to assess, local concentrations after stent deployment at the
cellular level are likely to be significantly higher than systemic
levels due to the lipophilic properties of these agents, which
tend to accumulate in the vessel wall.8,29– 31 Hence, the concen-
trations used in our study both in vivo and in vitro are likely to be
relevant for patients treated with DES.
When employed to prevent organ rejection after transplan-
tation, rapamycin target levels are around 10 ng/mL (corres-
ponding to 1028 mol/L). Interestingly, cases of thrombotic
microangiopathy have been described during treatment with rapa-
mycin (with or without a calcineurin inhibitor) in transplant recipi-
ents with chronic graft-vs.-host disease as well as after renal
transplantation.32,33 Thrombotic complications were also observed
in patients treated with rapamycin after liver transplantation.33 The
concentrations used in our in vivo experiments are around 10-fold
higher than target levels after transplantation, which would explain
why these complications do not occur more frequently. However,
it is conceivable that under certain circumstances, rapamycin may
have a prothrombotic effect in patients receiving the drug to
prevent organ rejection.
In spite of the obvious success of DES, several shortcomings
have been noted since their introduction including the risk of
stent thrombosis.12 While some studies found similar thrombosis
Figure 2 Rapamycin inhibits mammalian target of rapamycin and enhances endothelial tissue factor expression in human endothelial cells. (A)
Rapamycin enhances TNF-a-induced TF expression in a concentration-dependent manner. *P, 0.02 vs. TNF-a alone. (B) Rapamycin comple-
tely abrogates p70S6K phosphorylation.17 Total levels of p70S6K remain unchanged. Blots are representative of two independent experiments.
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rates in first-generation DES and BMS,34,35 others have described
an increased risk in DES.7,10 –12 Even though long-term large-scale
studies are currently underway to assess this issue, the fear of stent
thrombosis remains high owing to the oftentimes severe clinical
consequences. The occurrence of stent thrombosis has been
reported both with everolimus- and zotarolimus-eluting stent
systems;36,37 as the number of patients studied and the follow-up
duration are still limited, it is so far impossible to infer, whether
Figure 3 Everolimus and zotarolimus induce tissue factor expression and surface activity. (A) Comparison of maximal increase in rapamycin-,
everolimus-, and zotarolimus-enhanced TF expression. *P, 0.02 and **P, 0.005 vs. TNF-a alone; ***P, 0.001 vs. TNF-a alone and
***P, 0.05 vs. everolimus (using ANOVA with Bonferroni’s correction). Blots are representative of at least three independent experiments,
and values are given as percentage of stimulation with TNF-a alone. (B) Rapamycin, everolimus, and zotarolimus enhance TNF-a-induced TF
surface activity. Values are given as percentage of stimulation with TNF-a alone. *P, 0.01 vs. TNF-a alone; n ¼ 3. Everolimus (C, upper panel)
and zotarolimus (C, lower panel) abrogate p70S6K phosphorylation. Total levels of p70S6K remain unchanged. Blots are representative of four
independent experiments. TF, tissue factor, Ra, rapamycin, Ev, everolimus, Zo, zotarolimus.
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the risk of stent thrombosis is increased in such second-generation
DES when compared with first-generation DES or BMS.
Several mechanisms of stent thrombosis are currently discussed,
of which delayed endothelial healing is presently thought to be
most relevant.12 Impaired re-endothelialization may be a particu-
larly important cause of stent thrombosis in conditions with local
inflammation, such as in ACS. In a recent autopsy study of patients
treated with DES for acute myocardial infarction, vessel healing at
the culprit site was indeed substantially delayed when compared
with those treated for stable angina, suggesting an increased
thrombotic risk in the former group of patients.38 Our data
demonstrating enhanced TF activity as well as increased arterial
thrombogenicity in the setting of mTOR inhibition by rapamycin
support the interpretation that TF may also play an important
role in the pathogenesis of stent thrombosis, which may be even
more pronounced in the inflammatory microenvironment of
acute myocardial infarction. Since the mouse injury model used
in this study is mainly confined to the endothelium without expos-
ing arterial wall smooth muscle cells previously shown to contain
prothrombin that is rapidly converted to thrombin after injury,39
this model probably underestimates the thrombotic stimulus
seen with usual angioplasty and stenting. Rapamycin-coated
stents elute about 80% of the drug by 30 days.4,5 However,
rapamycin easily penetrates cell walls due to its lipophilic proper-
ties resulting in long-term retention of the drug in arterial
tissue.29–31 Hence, the time course of re-endothelialization as
well as the kinetics of rapamycin release imply that rapamycin-
enhanced endothelial TF expression may potentially play a role
in the pathogenesis of acute and subacute stent thrombosis,
while it may be less relevant for late stent thrombosis. Importantly,
PT, which by virtue of its measurement is dependent on FVIIa and
exogenous TF, remained unchanged after treatment of mice with
rapamycin, indicating that an increase in vessel-wall-derived TF is
responsible for the observed enhanced thrombogenicity. To
expand on these observations, further studies are needed to inves-
tigate the extent and the pattern of TF expression in the arterial
wall after deployment of both first- and second-generation DES.
Furthermore, substances eluted from DES may have an effect
not only on the stented arterial segment, but also on the endo-
thelium distal to the stent. Indeed, impaired endothelial function
was demonstrated by quantitative coronary angiography in coron-
ary arteries distal to rapamycin-eluting stent implantation.40,41
Thus, rapamycin, everolimus, or zotarolimus may not only increase
TF in the stented segment, but also in endothelial cells in the
immediate vicinity as well as in the more distal circulation. Such
an effect may potentially contribute to no-reflow phenomena
after stent deployment.
While the current study compares the in vitro TF induction of
rapamycin, everolimus, and zotarolimus, it does not compare TF
activity and thrombus formation in vivo amongst the three drugs;
in order to do so correctly and adequately, measurement of
in vivo plasma levels over time of all three drugs as well as appro-
priate adjustment of the applied doses of the drugs would be
required, which was beyond the scope of the current study.
Instead, we demonstrate for the first time in vivo (as a
proof-of-principle) that rapamycin inhibits arterial mTOR activity,
increases arterial TF activity and promotes thrombus formation
without affecting systemic coagulation parameters. Given the
similar effect of everolimus and zotarolimus on TF expression as
well as on p70S6K phosphorylation in vitro, an increase in TF
activity and promotion of thrombus formation in vivo is neverthe-
less likely to occur with these two drugs as well.
In summary, this study reveals that inhibition of mTOR increases
TF activity and promotes arterial thrombosis in vivo, which may
favour the development of thrombosis in DES. As everolimus
and zotarolimus equally increase TF expression and activity in
vitro, these findings may be relevant for both first- and second-
generation DES.
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